Connecticut is currently home to 1263 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Do Probiotics Improve Recovery From Acute Constipation in Kids?
NCT05734833
Recruiting
The purpose of this study is to evaluate the potential benefit of adding probiotics to the standard treatment for children who present to the emergency department with acute constipation. Before evaluating probiotics as a single therapy, we believe it is prudent to evaluate for added benefit first. Specifically, we seek to determine if adding probiotics decreases the length of time to normal stool frequency, decreases the number of days with abdominal pain/cramping, and improves time to normal e... Read More
Gender:
All
Ages:
Between 6 months and 8 years
Trial Updated:
02/09/2023
Locations: Connecticut Chidlren's Medical Center, Hartford, Connecticut
Conditions: Constipation
Register for Updates
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
NCT03748186
Recruiting
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02464969
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: Connecticut Children's Medical Center Pharmacy, Hartford, Connecticut
Conditions: Venous Thromboembolism
Register for Updates
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
NCT02926690
Recruiting
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: Norwalk Hospital, Norwalk, Connecticut
Conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
Register for Updates
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564
Recruiting
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (G... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/08/2023
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Motor Function, Cognitive Function, Contrast Media
Register for Updates
Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis
NCT05561764
Recruiting
There is established evidence that patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Imipenem/cilastatin/relebactam is a novel broad spectrum intravenous beta-lactam/beta-lactamase inhibitor combination antibiotic with potent activity against multidrug resistant Gram-negative bacteria, including imipenem non-susceptible Pseudomonas aeruginosa. Relebactam has also been shown to restore imipenem activity in Burkholderia cepacia complex,... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
01/03/2023
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Acquiring and Targeting Heat Exposures Necessary for Action
NCT05678738
Recruiting
The purpose of this research study is to better understand ways that women and men differ physiologically, cognitively, physically, and cellularly to better prescribe helpful interventions that will prevent injury and risk of conditions like exertional heat illnesses or heatstroke. The main questions this project aims to answer are: What is the relative stress contributing to performance differences between women and men during intense exercise in extremely hot and humid environments in respons... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
12/28/2022
Locations: Human Performance Laboratory at the University of Connecticut, Storrs, Connecticut
Conditions: Heat Intolerance, Heat Stress, Fatigue; Heat
Register for Updates
Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis
NCT05314764
Recruiting
There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered antibiotic pharmacokinetics compared with non-CF patients. Cefiderocol is a newly approved broad spectrum intravenous siderophore cephalosporin antibiotic, which has potent in vitro activity against multidrug resistant Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter species, and Stenotrophomonas maltophilia, all pathogens implicated in CF pulmonary exacerbations. This study will deter... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2022
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Cystic Fibrosis, Pneumonia, Bacterial
Register for Updates
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
NCT04931823
Recruiting
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/16/2022
Locations: Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumor
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy
Gender:
All
Ages:
18 years and above
Trial Updated:
12/09/2022
Locations: GSK Investigational Site, New Haven, Connecticut
Conditions: Neoplasms
Register for Updates
Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System
NCT04881162
Recruiting
Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid Neuroprotection System when used for the transcarotid intervention of patients that have a failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2022
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Ischemic Stroke
Register for Updates
AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)
NCT04663867
Recruiting
The study is designed to evaluate the safety and efficacy of the AngioSafe Peripheral CTO Crossing System.
Gender:
All
Ages:
22 years and above
Trial Updated:
11/22/2022
Locations: Vascular Care Connecticut, Darien, Connecticut
Conditions: Peripheral Artery Occlusion, Peripheral Arterial Disease
Register for Updates